The journey from preclinical development to commercialization of a new biopharmaceutical is long and challenging. The entire process requires persistence, adaptability, and strategic foresight. Only with a well-coordinated effort across disciplines and business functions can a new biologic drug successfully advance from laboratory to market. Partnering with a CDMO can be invaluable in navigating such challenges to provide flexibility, enabling drug sponsors to focus on their core competencies while relying on their partners to handle the intricacies of manufacturing and regulatory compliance. Such partnerships can reduce risks significantly and help ensure that a new biologic reaches the market as efficiently as possible. Learn key considerations for the journey to commercialization. Register or Login and hit Download Now to get the full Special Report.

This webcast features: Joe Payne, president & COO & Jeff Wolf, founder & CEO, Scorpius BioManufacturing. Too many promising biologic candidates are stalled without critical early-stage funding. Grant funding often falls short of the capital needed for pre-clinical and phase 1 manufacturing, but dilutive capital is hard to secure without positive early-stage data. In this webinar, learn about a hybrid model for capital-efficient access to cGMP manufacturing, process development, and analytical services for early-stage biotech companies through in-kind equity investment. Hear from Scorpius’ president and founder about why this US biologics CDMO was inspired to develop an innovative funding model to support innovative biotech companies. Thank you for your interest in this webcast. You may submit your request to view the webcast, and you will receive a confirmation email with log-in details.